Ascendiant Capital Markets Initiates Coverage on Cyclo Therapeutics (NASDAQ:CYTH)

Ascendiant Capital Markets started coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH) in a research note released on Monday morning, Benzinga reports. The firm issued a buy rating and a $2.60 target price on the stock.

Cyclo Therapeutics Trading Up 2.3 %

Shares of CYTH opened at $1.33 on Monday. The firm has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $1.46. The firm has a market cap of $38.20 million, a PE ratio of -1.02 and a beta of -0.15. Cyclo Therapeutics has a 1-year low of $0.83 and a 1-year high of $2.57.

Cyclo Therapeutics (NASDAQ:CYTH) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.23) EPS for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%. The firm had revenue of $0.31 million during the quarter.

Institutional Trading of Cyclo Therapeutics

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund V Management LLC acquired a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics makes up 80.8% of Founders Fund V Management LLC’s investment portfolio, making the stock its largest position. Founders Fund V Management LLC owned 2.11% of Cyclo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 68.55% of the company’s stock.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.